Shore Capital reissued their hold rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Tuesday, October 17th.
Several other research firms have also commented on AZN. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($73.90) price target on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($67.96) target price on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Tuesday, June 27th. Credit Suisse Group reiterated a neutral rating and issued a GBX 5,000 ($65.98) target price on shares of AstraZeneca plc in a research report on Monday, June 19th. Kepler Capital Markets reiterated a buy rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research report on Thursday, July 13th. Finally, Liberum Capital reiterated a buy rating and issued a GBX 5,500 ($72.58) target price on shares of AstraZeneca plc in a research report on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the stock. AstraZeneca plc currently has a consensus rating of Hold and an average target price of GBX 5,172.64 ($68.26).
Shares of AstraZeneca plc (LON AZN) opened at 5022.00 on Tuesday. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock’s market cap is GBX 63.58 billion. The company has a 50 day moving average price of GBX 4,991.11 and a 200-day moving average price of GBX 4,921.70.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/astrazeneca-plc-azn-rating-reiterated-by-shore-capital.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.